Literature DB >> 35734972

Association of Epicardial Adipose Tissue Thickness with Cardiovascular Risk in Acromegaly.

Bulent Can1, Fatma Olcay Coskun2, Sercin Ozkok3, Mumtaz Takir1.   

Abstract

Objective: Acromegaly is a rare disease associated with increased mortality. Reports on coronary artery disease in acromegaly are controversial. This study aimed to investigate the possible association of epicardial adipose tissue thickness with cardiovascular risk in patients with acromegaly.
Methods: The study included 38 patients followed up with the diagnosis of acromegaly and 29 healthy controls. Patients with acromegaly were divided into controlled and uncontrolled acromegaly groups based on insulin-like growth factor-1 levels. Epicardial adipose tissue thickness measurements were obtained from chest computed tomography, and laboratory data were extracted from patient files.
Results: Twenty-nine patients (76.3%) had controlled acromegaly. Eleven patients with acromegaly had diabetes mellitus (28.9%), 18 (47.4%) had hypertension, and 27 (71%) had a concomitant chronic disease. Epicardial adipose tissue thickness was significantly increased in the acromegaly group (p<0.001). No significant difference was observed between the controlled and uncontrolled acromegaly groups in terms of the epicardial adipose tissue thickness. Age was the only parameter that was significantly correlated with the epicardial adipose tissue thickness. When the Framingham risk score was calculated, the 10-year cardiovascular risk of patients with acromegaly was 5.63%. Conclusions: The epicardial adipose tissue thickness is increased in acromegaly. However, this increase may not have clinical relevance in terms of cardiovascular risk. ©Copyright 2022 by the Istanbul Medeniyet University / Medeniyet Medical Journal published by Galenos Publishing House.

Entities:  

Keywords:  Acromegaly; cardiovascular risk; epicardial adipose tissue

Year:  2022        PMID: 35734972      PMCID: PMC9234366          DOI: 10.4274/MMJ.galenos.2022.42492

Source DB:  PubMed          Journal:  Medeni Med J        ISSN: 2149-4606


  31 in total

1.  Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk.

Authors:  Carlos Reyes-Vidal; Jean Carlos Fernandez; Jeffrey N Bruce; Celina Crisman; Irene M Conwell; Jane Kostadinov; Eliza B Geer; Kalmon D Post; Pamela U Freda
Journal:  J Clin Endocrinol Metab       Date:  2014-08-19       Impact factor: 5.958

2.  Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography.

Authors:  Salvatore Cannavo; Barbara Almoto; Giovanni Cavalli; Stefano Squadrito; Giovanni Romanello; Maria Teresa Vigo; Francesco Fiumara; Salvatore Benvenga; Francesco Trimarchi
Journal:  J Clin Endocrinol Metab       Date:  2006-07-11       Impact factor: 5.958

3.  Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly.

Authors:  A Colao; S Spiezia; G Cerbone; R Pivonello; P Marzullo; D Ferone; C Di Somma; A P Assanti; G Lombardi
Journal:  Clin Endocrinol (Oxf)       Date:  2001-04       Impact factor: 3.478

4.  Coronary microvascular dysfunction may be related to IGF-1 in acromegalic patients and can be restored by therapy.

Authors:  Sara Tellatin; Pietro Maffei; Elena Osto; Francesca Dassie; Giulia Famoso; Roberta Montisci; Chiara Martini; Francesco Fallo; Martina Perazzolo Marra; Roberto Mioni; Sabino Iliceto; Roberto Vettor; Francesco Tona
Journal:  Atherosclerosis       Date:  2017-12-24       Impact factor: 5.162

5.  Low risk of coronary artery disease in patients with acromegaly.

Authors:  Cintia Marques Dos Santos Silva; G A B Lima; I C M Volschan; I Gottlieb; L Kasuki; L Vieira Neto; M R Gadelha
Journal:  Endocrine       Date:  2015-05-17       Impact factor: 3.633

6.  Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly.

Authors:  Cigdem Ozkan; Alev Eroglu Altinova; Ethem Turgay Cerit; Cagri Yayla; Asife Sahinarslan; Duygu Sahin; Aylin Sepici Dincel; Fusun Balos Toruner; Mujde Akturk; Metin Arslan
Journal:  Pituitary       Date:  2015-10       Impact factor: 4.107

7.  Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly.

Authors:  Anna Aulinas; Iris Crespo; David Viladés; Ruben Leta; Eulàlia Urgell; Betina Biagetti; Susan M Webb; Elena Valassi
Journal:  Clin Endocrinol (Oxf)       Date:  2016-12-02       Impact factor: 3.478

8.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

Review 9.  Epidemiology of acromegaly: review of population studies.

Authors:  Aikaterini Lavrentaki; Alessandro Paluzzi; John A H Wass; Niki Karavitaki
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

10.  A consensus on the diagnosis and treatment of acromegaly complications.

Authors:  S Melmed; F F Casanueva; A Klibanski; M D Bronstein; P Chanson; S W Lamberts; C J Strasburger; J A H Wass; A Giustina
Journal:  Pituitary       Date:  2013-09       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.